Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

BACKGROUND: Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptor-α to inhibit IL-6 signalling. The aim of this study was to compare the effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabay, Cem, Burmester, Gerd R., Strand, Vibeke, Msihid, Jérôme, Zilberstein, Moshe, Kimura, Toshio, van Hoogstraten, Hubert, Boklage, Susan H., Sadeh, Jonathan, Graham, Neil M. H., Boyapati, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137491/
https://www.ncbi.nlm.nih.gov/pubmed/32264972
http://dx.doi.org/10.1186/s13075-020-02163-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137491/
https://www.ncbi.nlm.nih.gov/pubmed/32264972
http://dx.doi.org/10.1186/s13075-020-02163-6

Ejemplares similares